Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well imatinib mesylate works in treating patients with
stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.